Literature DB >> 11911332

Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.

Javier P Gisbert1, Fernando Gomollón, José Maté, José María Pajares.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11911332     DOI： 10.1023/a:1017987229718

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  112 in total

1.  Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

Authors:  C Florent; A Cortot; P Quandale; T Sahmound; R Modigliani; E Sarfaty; P Valleur; J L Dupas; M Daurat; J L Faucheron; E Lerebours; F Michot; J Belaiche; N Jacquet; J C Soulé; N Rothman; J P Gendre; M Malafosse
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-03       Impact factor: 2.566

2.  Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.

Authors:  P Rutgeerts
Journal:  Aliment Pharmacol Ther       Date:  1989-04       Impact factor: 8.171

3.  Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.

Authors:  M Campieri; G A Lanfranchi; G Bazzocchi; C Brignola; F Sarti; G Franzin; A Battocchia; G Labo; P R Dal Monte
Journal:  Lancet       Date:  1981-08-08       Impact factor: 79.321

4.  Second trial of mesalamine therapy in the treatment of active Crohn's disease.

Authors:  J Singleton
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

5.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.

Authors:  C N Williams; G Haber; J A Aquino
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

6.  Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.

Authors:  M Campieri; R De Franchis; G Bianchi Porro; T Ranzi; G Brunetti; L Barbara
Journal:  Scand J Gastroenterol       Date:  1990-07       Impact factor: 2.423

7.  A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.

Authors:  R D Cohen; D M Woseth; R A Thisted; S B Hanauer
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

8.  Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.

Authors:  M Robinson; S Hanauer; R Hoop; A Zbrozek; C Wilkinson
Journal:  Aliment Pharmacol Ther       Date:  1994-02       Impact factor: 8.171

Review 9.  Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.

Authors:  M A Peppercorn
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

10.  A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

Authors:  O O Thomsen; A Cortot; D Jewell; J P Wright; T Winter; F T Veloso; M Vatn; T Persson; E Pettersson
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245
View more
  28 in total

1.  Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.

Authors:  Isaac M Westwood; Simon J Holton; Fernando Rodrigues-Lima; Jean-Marie Dupret; Sanjib Bhakta; Martin E M Noble; Edith Sim
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

2.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

3.  Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients.

Authors:  Maribel Rodríguez-Torres; Jose F Rodríguez-Orengo; Carlos F Ríos-Bedoya; Alberto Fernández-Carbia; Rosa Salgado-Mercado; Acisclo M Marxuach-Cuétara
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

Review 4.  Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs.

Authors:  Jennifer Poh; Sandra Knowles
Journal:  Can J Hosp Pharm       Date:  2014-01

Review 5.  IBD in the Elderly: Management Challenges and Therapeutic Considerations.

Authors:  Vivy Tran; Berkeley N Limketkai; Jenny S Sauk
Journal:  Curr Gastroenterol Rep       Date:  2019-11-27

6.  Short-term effect and adverse events of adalimumab versus placebo in inducing remission for moderate-to-severe ulcerative colitis: a meta-analysis.

Authors:  Zheng Yang; Xiao-Qing Ye; Yu-Zhen Zhu; Zhou Liu; Ying Zou; Ying Deng; Can-Can Guo; Sushil Kumar Garg; Jin-Shan Feng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

7.  Intestinal organoids containing poly(lactic-co-glycolic acid) nanoparticles for the treatment of inflammatory bowel diseases.

Authors:  Zahra Davoudi; Nathan Peroutka-Bigus; Bryan Bellaire; Michael Wannemuehler; Terrence A Barrett; Balaji Narasimhan; Qun Wang
Journal:  J Biomed Mater Res A       Date:  2017-12-21       Impact factor: 4.396

8.  Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies.

Authors:  Fernando Bermejo; Javier P Gisbert
Journal:  Ther Adv Chronic Dis       Date:  2010-05       Impact factor: 5.091

Review 9.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 10.  Crohn's disease.

Authors:  Alexander C von Roon; George E Reese; Timothy R Orchard; Paris P Tekkis
Journal:  BMJ Clin Evid       Date:  2007-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.